Department of Medical Oncology, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium.
Cancer Treat Rev. 2011 Aug;37(5):385-90. doi: 10.1016/j.ctrv.2010.11.005. Epub 2010 Dec 22.
In 1997, the anti-CD20 monoclonal antibody (MAb) rituximab became the first MAb approved for clinical use in oncology, and ushered in a new era of rationally designed targeted agents in cancer therapeutics. It is currently approved for use in non-Hodgkin lymphoma (NHL), chronic lymphoid leukemia (CLL), and rheumatoid arthritis (RA). Rituximab is non-mutagenic, associated with low treatment-related toxicity, and few, if any, long term adverse events, making it an attractive agent to be tried in off-label settings like Hodgkin lymphoma (HL). HL consists of two distinct subtypes - classic HL (cHL) and lymphocyte predominant HL (LPHL). CD20 is present in virtually all patients with LPHL, and in a significant minority of patients with cHL. In this CD20 positive sub-population, the use of rituximab is a rational intervention strategy. Rituximab has been used in patients with cHL as well as LPHL with good efficacy. In this article, we provide a clinically-oriented overview of the use of rituximab in the different sub-types of HL, and report updated results of our series of 8 LPHL patients treated with rituximab. A systematic review of the literature is also presented.
1997 年，抗 CD20 单克隆抗体（MAb）利妥昔单抗成为第一种获准在肿瘤学临床应用的 MAb，开创了癌症治疗中合理设计靶向药物的新时代。目前，它已获准用于非霍奇金淋巴瘤（NHL）、慢性淋巴细胞白血病（CLL）和类风湿关节炎（RA）。利妥昔单抗是非致突变的，与低治疗相关毒性相关，并且几乎没有长期不良事件，使其成为一种有吸引力的药物，可以在霍奇金淋巴瘤（HL）等标签外环境中尝试使用。HL 由两个不同的亚型组成——经典 HL（cHL）和淋巴细胞为主型 HL（LPHL）。CD20 几乎存在于所有 LPHL 患者和少数 cHL 患者中。在这个 CD20 阳性亚群中，使用利妥昔单抗是一种合理的干预策略。利妥昔单抗已用于 cHL 患者和 LPHL 患者，疗效良好。本文提供了一个临床导向的概述，介绍了利妥昔单抗在不同 HL 亚型中的应用，并报告了我们治疗的 8 例 LPHL 患者的系列更新结果。还进行了文献的系统评价。
